CN105963691B - Streptococcus pneumoniae vaccine - Google Patents
Streptococcus pneumoniae vaccine Download PDFInfo
- Publication number
- CN105963691B CN105963691B CN201610524959.4A CN201610524959A CN105963691B CN 105963691 B CN105963691 B CN 105963691B CN 201610524959 A CN201610524959 A CN 201610524959A CN 105963691 B CN105963691 B CN 105963691B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- protein
- streptococcus pneumoniae
- polypeptide
- immunization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940124858 Streptococcus pneumoniae vaccine Drugs 0.000 title claims description 6
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 9
- 102220485918 Glutamate dehydrogenase 2, mitochondrial_K92S_mutation Human genes 0.000 claims description 3
- 102220624649 Pleckstrin homology domain-containing family O member 1_K42C_mutation Human genes 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 102220056032 rs727504689 Human genes 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 15
- 108091007433 antigens Proteins 0.000 abstract description 15
- 230000003053 immunization Effects 0.000 abstract description 13
- 238000002649 immunization Methods 0.000 abstract description 13
- 239000000427 antigen Substances 0.000 abstract description 12
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract description 9
- 102000008300 Mutant Proteins Human genes 0.000 abstract description 3
- 108010021466 Mutant Proteins Proteins 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 2
- 229940124733 pneumococcal vaccine Drugs 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 206010061372 Streptococcal infection Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940031670 conjugate vaccine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 241000743339 Agrostis Species 0.000 description 1
- -1 AlK (S04)2 Chemical class 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000680505 Streptococcus pneumoniae WU2 Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- DFLVMTLZOVLAAA-UHFFFAOYSA-N n,n-diamino-4-[4-(diaminoamino)phenyl]aniline Chemical compound C1=CC(N(N)N)=CC=C1C1=CC=C(N(N)N)C=C1 DFLVMTLZOVLAAA-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a pneumococcal vaccine and a preparation method thereof, wherein the pneumococcal vaccine is prepared by mixing an S3CS recombinant antigen or a mutant protein antigen thereof with an adjuvant. The vaccine can be used for immunization, improves the protection of the body against streptococcus pneumoniae, and can produce specific antibodies. The preparation method is simple and is suitable for the requirement of large-scale industrial production.
Description
Technical Field
The invention relates to a vaccine, in particular to a streptococcus pneumoniae vaccine.
Background
Infections caused by pneumococci (the lung chain) are a major cause of morbidity and mortality worldwide. Pneumonia, febrile bacteremia and meningitis are the most common manifestations of invasive pneumococcal disease, and bacterial spread in the respiratory tract can lead to middle ear infections, sinusitis or recurrent bronchitis. Non-invasive manifestations are usually less severe, but more common, than invasive diseases. The likelihood of pneumococcal disease onset during influenza is further increased due to the spread of antibiotic-resistant infections, and pneumococcal pneumonia often follows influenza infection. The disease caused by streptococcus pneumoniae has become an important public health problem worldwide. Pneumococci have become the first killer of children worldwide.
The fatality rate of pneumonia in China is 16.4%, wherein the fatality rate of middle-aged and old people over 50 years old and infants under 1 year old is respectively as high as 28.6% and 22.0%. The carriage rate of pneumococcus in healthy children in China is high, and data statistics shows that the carriage rate of pneumococcus in healthy children in northern regions is 24.2%, and the carriage rate of pneumococcus in southern regions is 31.3%. Which is a significant cause of death in children under the age of 5. The main reasons are that the development of the immune system of infants is not complete and the immunity is weak. And the younger the infant, the weaker the immunity.
The pneumococcus has about 90 serotypes (strains), and the statistics of China show that the serotypes of the pneumococcus infected strains are 5,6, 19, 23, 14, 2 and 4 in turn. A study in which 860 pneumococcal isolates were collected showed that 109 (12.7%) showed serogroup 6 with 100% erythromycin resistance in pneumococcal serotype 6 in china, with types 6A, 6B and 6C of 62 (56.9%), 38 (34.9%) and 9 (8.2%) respectively.
23-valent pneumococcal vaccines produced by China biotechnology group Chengdu biological product research institute are prepared by selecting 23 most common pathogenic bacteria (1, 2,3,4,5,6B, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), fermenting, culturing, separating and purifying various polysaccharides on pneumococcal capsules respectively, and mixing the polysaccharides in equal proportion to prepare the vaccine.
Bacterial polysaccharides are a thymus-independent antigen, which differs from thymus-dependent antigens primarily in that the former do not require the help of T lymphocytes to produce antibodies. Polysaccharide vaccines therefore suffer from the following problems: (1) only weak immune response can be generated in the bodies of young animals or infants, even no immune response can be generated, and the immune response is enhanced along with the increase of the age; (2) generating low affinity antibodies; (3) only produces transient immune response, and does not have immune memory and immune enhancement effect during repeated inoculation; (4) immune tolerance is easy to generate; (5) the common adjuvant has no easy effect of immune enhancement on the antigen. The protective rate of the 23-valent polysaccharide vaccine for invasive lung chain infection is 50-70%. And can only be used for inoculation of people over 2 years old, and the peak onset age of pneumonia is 6-12 months old.
A number of specific polypeptides having antigenicity are described in PCT patent No. W098/18930, published 5/7 of 1998 entitled "antigens and vaccines for Streptococcus Pneumoniae" (Streptococcus Pneumoniae antigens and vaccines), but there is no report on the biological activity of these polypeptides.
Thus, the urgent need to use streptococcal antigens as components of vaccines for the prevention and/or treatment of streptococcal infections is becoming increasingly important.
Disclosure of Invention
The invention provides a streptococcus pneumoniae vaccine, wherein the protein amino acid sequence in the vaccine is shown as SEQ ID NO:1 is shown.
Other aspects of the invention provide vectors comprising a polynucleotide of the invention operably linked to an expression control region, host cells transfected with said vectors and methods of producing a polypeptide comprising culturing said host cells under conditions suitable for expression of the gene.
In another aspect, novel polypeptides encoded by the polynucleotides of the invention are provided.
According to one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide having at least 95% identity to a polypeptide selected from the group consisting of SEQ ID NO. 1.
According to one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide having at least 90% identity to a polypeptide selected from the group consisting of SEQ ID NO. 1.
According to one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide having at least 85% identity to a polypeptide selected from the group consisting of SEQ ID NO. 1.
According to one aspect of the invention, there is provided an isolated polynucleotide encoding a polypeptide having at least 80% identity to a polypeptide selected from the group consisting of SEQ ID NO. 1.
In a particular embodiment, the invention also relates to a chimeric polypeptide comprising one or several polypeptides as defined in the conjugated protein or fragments, analogues or derivatives thereof.
The coupling protein is coupled and combined protein which is diphtheria toxoid, tetanus toxoid, carrier protein CRM197, hemophilus influenzae surface protein HiD, pertussis Prn surface protein, pertussis Fha antigen and/or streptococcus pneumoniae surface protein PspA.
In a specific embodiment, the polypeptide or chimeric polypeptide according to the invention is antigenic.
In a specific embodiment, the polypeptide or chimeric polypeptide according to the invention is capable of eliciting an immune response in an individual.
In a particular embodiment, the invention also relates to polypeptides capable of producing antibodies with binding specificity for a polypeptide or chimeric polypeptide as defined in the present invention.
An antibody that is "binding-specific" means that the antibody is capable of recognizing and binding to a particular polypeptide, but does not substantially recognize and bind to other molecules in a sample, such as a biological sample that naturally contains the selected peptide. The specific binding capacity of the selected polypeptide as antigen can be determined by enzyme-linked immunosorbent assay (ELISA).
According to the present invention, the polypeptide includes both polypeptides and chimeric polypeptides. Also included are polypeptides that have been altered in biological and pharmacological properties by fusion with other compounds, for example, polyethylene glycol to increase half-life; fused to leader or secretory sequences to
The purification is convenient; also prepro (prepro) sequences and fusions to pro (pro) sequences and (poly) saccharides.
Furthermore, where some amino acid regions are polymorphic, it may be more desirable to alter one or more particular amino acids to more effectively mimic different epitopes on different strains of Streptococcus.
The mutation is obtained by screening nearly 800 mutations possibly by the applicant.
The mutation site is shown in SEQ ID NO:1, or a pharmaceutically acceptable salt thereof. F23V (indicating the substitution of the F amino acid at position 23 with V), K42C, P60T, K92S, P122D, E133F, D180S, F189H, K243S, I304G, L320Y, V329P, F332K, I339V, I352M, F361W, K369P, S372K, F380M, L401E.
In addition, polypeptides of the invention can be modified by phthalylation of the terminal amino group (e.g., acetylphthalylation or thioacetic acid phthalylation) and terminal carboxyphthalylation (e.g., with ammonia or methylamine), to provide stability and enhance hydrophobicity for attachment or binding to a support or other molecule.
According to another aspect, the present invention provides a vaccine composition comprising at least one or several streptococcal polypeptides of the present invention in admixture with a pharmaceutically acceptable carrier diluent or adjuvant. Suitable adjuvants include oils, such as Freund's complete or incomplete adjuvant; salts, such as AlK (S04)2, AINa (S04)2, A1NH4(S04) a, silica, kaolin; carbon polynucleotides such as poly IC and poly AU. Preferred adjuvants include Querca (QuilA) and aluminum hydrogel (Alhydrogel). The vaccine of the present invention can be administered parenterally by injection, bolus infusion, nasopharyngeal absorption, cutaneous absorption, or buccal administration. Pharmaceutically acceptable carriers also include tetanus toxoid.
The vaccine compositions of the invention are useful for treating or preventing streptococcal infections and/or diseases and conditions caused by streptococcal infection as described in p.r.murry (eds.), e.j.baron, m.a.pfaller, f.c.tenover and r.h.yolken et al, Manual of clinical microbiology, ASM Press, Washington, d.c. 6 th edition, 1995, page 1482 (which is incorporated herein by reference).
In one embodiment, the vaccine composition of the present invention is used to treat and prevent meningitis, otitis media, bacteremia and pneumonia. In a particular embodiment, the vaccine composition of the invention is used for the treatment and prevention of infection with and/or disease and condition following infection with streptococci, in particular with streptococcus pneumoniae, group a streptococci (streptococcus pyogenes) [ group aspergillus (pyogenes) ], group B streptococci (GBS or streptococcus agalactiae) [ group bstreptrepus (GBS or agalactiae) ], dysgalactiae (dysgalactiae), papilla bacteria (uberis), agrostis (nocardia) and staphylococcus aureus (streptococcus aureus). In a specific embodiment, the infection by streptococcus is streptococcus pneumoniae.
In a particular embodiment, the vaccine is administered to individuals at risk of streptococcal infection, such as infants, the elderly and immunocompromised individuals.
As used herein, "individual" includes mammals. In one embodiment the mammal is a human.
The vaccine composition is preferably administered in a unit dose of about 0.001 to 100p, g/kg (antigen/body weight), more preferably 0.01 to 1Opg/kg, most preferably 0.1 to 1p, g/kg, with one to three administrations occurring at one to six week intervals between immunizations.
The effect of sense: the invention provides a protein with better immunogenicity, a vaccine prepared from the protein can provide better immune protection capability of streptococcus pneumoniae, the protein is simple to prepare, has low cost, has no side effect on human bodies, and is suitable for large-area popularization.
Detailed Description
EXAMPLE 1 expression of proteins
And (2) taking DNA of streptococcus pneumoniae as a template, and amplifying by designing a primer to obtain the DNA of SEQ ID NO:1, and then recovering the PCR product from the agarose gel by using QIAquick gel extraction kit of QIAGEN (Chatworth, CA), digesting the PCR product with Superlinker vector pSL301(Invitrogen, San Diego, CA), and recovering the PCR product from the agarose gel by using QIAquick gel extraction kit of QIAGEN (Chatworth, CA), ligating the restriction-digested genomic DNA fragment with the restriction-digested pSL301 vector, and ligating the ligated product with a plasmid of 5a E.coli, and purifying the recombinant plasmid of pSL301 (SL 301) containing the target gene by using QIAGEN kit, and sequencing and identifying the recombinant plasmid to be correct.
The target gene is constructed into a pET-32c (+) expression vector (Novagen, Madison, WT) through enzyme digestion connection, then is transformed into BL21 cells for prokaryotic expression, a protein form expressed by a supernatant is obtained through conventional expression, and the target protein with the concentration of 100mg/mL is obtained through column purification.
Example 2 obtaining of muteins
Introduction of mutation points
(1) Designing a corresponding mutagenesis primer according to a corresponding mutation site, and mutating an amino acid site corresponding to a wild type on the corresponding S3CS gene by adopting a PCR (polymerase chain reaction) site-specific mutation method; the mutation site is shown in SEQ ID NO:1, or a pharmaceutically acceptable salt thereof. F23V (indicating the substitution of the F amino acid at position 23 with V), K42C, P60T, K92S, P122D, E133F, D180S, F189H, K243S, I304G, L320Y, V329P, F332K, I339V, I352M, F361W, K369P, S372K, F380M, L401E.
(2) After the PCR product is recovered and purified by glue, carrying out enzyme digestion by using restriction enzyme, connecting the product with a plasmid pSL301 vector fragment subjected to the same enzyme digestion, and transforming escherichia coli DH5 α competent cells;
(3) and identifying the recombinant plasmid: and (3) identifying the recombinant plasmid by enzyme digestion and PCR (polymerase chain reaction) methods, and carrying out sequencing inspection, thereby obtaining the mutated nucleotide sequence.
The mutated S3CS gene was expressed according to the expression method of example 1, and the protein concentration was adjusted to 100mg/mL after purification.
Example 3 evaluation of antibody-producing Effect of pneumococcal protein vaccine
12-14g female 3-week-old BALB/c. pups, randomly divided into 23 groups of 20 mice each, were intraperitoneally injected with a conjugate vaccine formulated according to example 1 and 2 protein with Al (OH)3 as an immunoadjuvant, a commercial 13-valent pulmonary chain conjugate vaccine, a blank control (PBS), respectively.
Injections were given 3 times per week 0, 2, 4 of the program, each mouse containing 0.5ml of protein (0.5ug protein). Blood was collected from each experimental group 7 days after the injection of the third needle, and serum was separated and stored at-20 ℃ for future use.
For the detection of the protein antibody titer, the protein was dissolved in 0.05mol/L carbonate buffer solution of pH9.6 by indirect ELISA, coated with an ELISA plate at a concentration of 20ug/ml, and blocked with 2% BSA solution. During the experiment, the serum to be detected is diluted by 100, 200, 400, 800, 1600, 3200, 6400, 12800, 25600, 51200, 102400, 204800 and 409600 times, then is added into an ELISA plate, the ELISA plate is placed at 37 ℃ for reaction for 40min, and after the ELISA plate is washed conventionally, a goat-anti-mouse secondary antibody marked by horseradish peroxidase is added. Buffer without serum was also added as a negative control. The color is developed by using tetraaminobenzidine, and the A value is read at the wavelength of 450nm by using an enzyme-labeling instrument. The ratio of the A value in each well to the A value in the negative well was calculated, but the largest dilution factor when the ratio was more than 2.1 was the antibody titer in serum, the titers of 20 mice were geometrically averaged, and the log value was calculated at the bottom of 20, and the results are shown in Table 1.
It is seen from the data that the protein vaccine of the present invention and the corresponding mutant protein vaccine have significantly enhanced immune response to lung chain polysaccharide in mice, and also have enhanced ability to produce antibodies compared to the commercially available vaccine.
Example 4 evaluation of Effect of immunized mice
1) The first immunization, 2mg of S3CS or its mutated recombinant protein antigen is diluted with PBS, and Al (OH)3 with the concentration of 1mg/mL is added; injecting with No. 5 semi-type needle, subcutaneous injection of inguinal, plantar and dorsal parts at two sides, with injection amount of l00uL for each BALB/C mouse, and setting positive control group, negative control group and blank control group;
2) the second immunization, the second immunization is carried out on the 14 th day, the immunization components are the same, the amount of the protein antigen injected is 1/2 of the first immunization, and the immunization route is the same as the above;
3) the third immunization, the third immunization is carried out on day 21, the immunization components are the same as above, the amount of the protein antigen injected is the same as that of the second immunization, and the immunization way is the same as above;
on day 14, a lethal dose is adopted, the streptococcus pneumoniae strain WU2 viable bacteria is injected into tail vein to carry out a virus challenge experiment, the amount of the bacteria injected into each BALB/C mouse is 1.5 × 109CFU, and the survival rate of each group of mice is counted after 14 days of observation. The results are shown in Table 2.
Table 2 shows; the average immune protection rate of the negative control group and the blank control group is 0 percent respectively, and the antigen protein or the mutant protein thereof has the protection characteristic of about 100 percent and has improved effect compared with the vaccine in the prior art.
Evaluation of safety
After the challenge experiment, the mice immunized by the protein are continuously cultured for 1 month, and are dissected, so that the organs of the mice are normal and have no variation. This is sufficient to show that the vaccine of the present invention is safe and reliable.
The above description is only for the preferred embodiment of the present invention, and is not intended to limit the scope of the present invention; it is intended that the following claims be interpreted as including all such alterations, modifications, and equivalents as fall within the true spirit and scope of the invention.
Sequence listing
The beautiful silk of (110)
Streptococcus pneumoniae vaccine < 120 >
〈160〉1
〈210〉1
〈211〉887
〈212〉PRT
Artificial sequence of < 213 >
〈400〉S3CS
1 MYTFILMLLD FLKNHDFHFF MLFFVFILIR WAVIYFHAVR YKSYSCSVSD EKLFSSVIIP
61 VVDEPLNLFE SVLNRISRHK PSEIIVVING PKNERLLKLC HDFNEKLENN MTPIQCYYTP
121 VPGKRNAIRV GLEHVDSQSD ITVLVDSDTV WTPRTLSELL KPFVCDKKIG GVTTRQRIFD
181 PERNLVTMFA NLLEEIRAEG SMKAMSVTGK VGCLPGRTIA FRTEILRECI HEFMNETFMG
241 FHKEVSDDRS LTNLTLKKGY KTVMQDTSVV YTDAPTSWKK FIRQQLRWAE GSQYNNLKMT
301 PWMIRNAPLM FFIYFTDMIL PMLLISFGVN IFLLKILNIT TVVYTASWLE IILYVLFGMI
361 FSFGGRNFKA MSRMKWYYVF LIPVFIIVLS IIMCPIRLLG LMRCSDDLGW GTRNLIEGGG
421 SGGGSGGGSG GGSGGGSMSK YKELAKNTGI FALANFSSKI LIFLLVPIYT RVLTTTEYGF
481 YDLVYTTIQL FVPILTLNIS EAVMRFLMKD GVSKKSVFSI AVLDIFIGSI AFALLLLVNN
541 LFSLSDLISQ YSIYIFVIFV FYTLNNFLIQ FSKGIDKIGV TAISGVISTA VMLAMNVILL
601 VVFDWGLLGF FIANVCGYVI PCIYIVSRLR LWELFEIKID KKLQWEMVYY ALPLVLNILS
661 WWVNNTSDRY IVTAIVGIQA SAIISVAYKI PQILSTISAI FIQSWQISAI KIQEDKSDTT
721 FVSNMLLYYN ALLLIIASGI ILFVKPISNI LFGISFYSAW ELVPFLIISS LFNAISGCIG
781 AIMGAKMDTH NIAKSALVGM IANIILNIVL TFLMGPQGIT ISTLIASFLI FYMRKDSVKE
841 INSETYRAIY LSWILLVVEA CLLIYMDFII GALIAMVINL FLLKDVI
Claims (1)
1. A streptococcus pneumoniae vaccine comprising an antigenic protein and an adjuvant, wherein the antigenic protein is SEQ ID NO:1, or a sequence as set forth in SEQ ID NO:1, and specific mutation sites of the sequence subjected to point mutation are F23V, K42C, P60T, K92S, P122D, E133F, D180S, F189H, K243S, I304G, L320Y, V329P, F332K, I339V, I352M, F361W, K369P, S372K, F380M or L401E.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610524959.4A CN105963691B (en) | 2016-07-03 | 2016-07-03 | Streptococcus pneumoniae vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610524959.4A CN105963691B (en) | 2016-07-03 | 2016-07-03 | Streptococcus pneumoniae vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105963691A CN105963691A (en) | 2016-09-28 |
CN105963691B true CN105963691B (en) | 2020-05-01 |
Family
ID=56953859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610524959.4A Active CN105963691B (en) | 2016-07-03 | 2016-07-03 | Streptococcus pneumoniae vaccine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105963691B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024079A (en) * | 2006-02-17 | 2007-08-29 | 福州昌晖生物工程有限公司 | Pneumo-streptococcal-polysaccharide adventitia jointed vaccine and preparing method |
CN101977927A (en) * | 2008-03-17 | 2011-02-16 | 英特塞尔股份公司 | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
CN103830723A (en) * | 2012-11-26 | 2014-06-04 | 天士力制药集团股份有限公司 | Preparation method of streptococcus pneumoniae capsular polysaccharide protein conjugate vaccine |
CN103893751A (en) * | 2014-03-26 | 2014-07-02 | 天津康希诺生物技术有限公司 | Pneumococcal polysaccharide and protein conjugated vaccine and preparation method thereof |
CN104844712A (en) * | 2015-04-03 | 2015-08-19 | 长春百克生物科技股份公司 | Streptococcus pneumonia protein antigen, and preparation method and application thereof |
CN105008539A (en) * | 2012-11-07 | 2015-10-28 | 格林考瓦因有限公司 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
-
2016
- 2016-07-03 CN CN201610524959.4A patent/CN105963691B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024079A (en) * | 2006-02-17 | 2007-08-29 | 福州昌晖生物工程有限公司 | Pneumo-streptococcal-polysaccharide adventitia jointed vaccine and preparing method |
CN101977927A (en) * | 2008-03-17 | 2011-02-16 | 英特塞尔股份公司 | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
CN105008539A (en) * | 2012-11-07 | 2015-10-28 | 格林考瓦因有限公司 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
CN103830723A (en) * | 2012-11-26 | 2014-06-04 | 天士力制药集团股份有限公司 | Preparation method of streptococcus pneumoniae capsular polysaccharide protein conjugate vaccine |
CN103893751A (en) * | 2014-03-26 | 2014-07-02 | 天津康希诺生物技术有限公司 | Pneumococcal polysaccharide and protein conjugated vaccine and preparation method thereof |
CN104844712A (en) * | 2015-04-03 | 2015-08-19 | 长春百克生物科技股份公司 | Streptococcus pneumonia protein antigen, and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
46株肺炎链球菌的血清型别和毒力因子基因的保守性分析;刘孟涓 等;《临床检验杂志》;20131215(第12期);934-937 * |
ACCESSION NO.AEP95727.1;Denapaite,D.et al.;《GenBank》;20111011;1 * |
Denapaite,D.et al..ACCESSION NO.AEP95727.1.《GenBank》.2011,1. * |
肺炎链球菌蛋白质疫苗研究进展;曹炬 等;《国际检验医学杂志》;20070331(第03期);214-216 * |
Also Published As
Publication number | Publication date |
---|---|
CN105963691A (en) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8529913B2 (en) | Immunogenic compositions for Streptococcus pyogenes | |
US20220267385A1 (en) | Immunogenic fusion protein | |
EP2908856B1 (en) | Immunogenic composition | |
AU2019338473A1 (en) | Multivalent pneumococcal vaccines | |
US20120135037A1 (en) | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same | |
US20180256698A1 (en) | Proline-rich peptides protective against s. pneumoniae | |
US11484584B2 (en) | Immunogenic complex for eliciting protective immunity against group B Streptococcus | |
US20230089151A1 (en) | Pneumococcal fusion protein vaccines | |
US20150273042A1 (en) | Pilus proteins and compositions | |
JP2001515723A (en) | Group A streptococcal vaccine | |
JP2020502075A (en) | Pneumococcal vaccine combining selected alpha-helical and proline-rich domains of pneumococcal surface protein A | |
CN105963691B (en) | Streptococcus pneumoniae vaccine | |
KR102139959B1 (en) | Antigens and antigen combinations | |
US8642049B2 (en) | Vaccine against group A beta hemolytic streptococcus and respective process for obtaining thereof | |
CN112449603A (en) | Streptococcal toxic shock syndrome | |
CN110898217B (en) | Streptococcus pneumoniae vaccine and preparation method thereof | |
US11357845B2 (en) | Protein antigens for vaccinating against nontypeable Haemophilus influenzae | |
CN117120081A (en) | Immunogenic fusion proteins | |
CN116769056A (en) | Fusion protein, purification preparation method and application | |
WO2004048575A2 (en) | Streptococcus pneumoniae surface polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: 100176 room 01-12, floor 1, building 1, No. 3, Yongchang North Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee after: Nuosa Union (Beijing) Biomedical Technology Co., Ltd Address before: 310027 Zhejiang University, 38 Zhejiang Road, Hangzhou, Zhejiang, Xihu District Patentee before: Zha Wenjuan |